HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a ...
Radiation Research, Vol. 188, No. 2 (August 2017), pp. 156-168 (13 pages) Rapid clinical triage of radiation injury patients is essential for determining appropriate diagnostic and therapeutic ...
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia and Lymphocyte Exhaustion Tivic Health® Systems, ...
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases ...
Military personnel enter active duty knowing there are risks involved. One risk that affects a small proportion of veterans is illness caused by radiation exposure during service. Most veterans don’t ...
FREMONT, CA / ACCESS Newswire / November 18, 2025 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage therapeutics company, today announced it has secured an exclusive Techwatch meeting with the ...
(RTTNews) - Pluri Inc. (PLUR), a biotechnology company specializing in cell-based solutions, announced on Monday that it is assessing its readiness to initiate mass production of PLX-R18, a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results